FDA Decision On CBD Use Could Run Up Against Chicken Or Egg Question
Executive Summary
Speakers at FDA's first-ever public hearing on using cannabis-derived ingredients in products subject to its oversight asked agency officials to look back further than history of drug research with cannabinoids to earlier than the origin of its regulations as it considers its decision. "CBD is a constituent inherent in hemp which has been marketed and used at least since the Civil War," says cannabis business attorney Rob Kight.
You may also be interested in...
Comments On Petition As Good As Public Hearing On NAC’s Use As Dietary Ingredient – US FDA
Agency "does not believe a hearing is necessary at this time given the other mechanisms at stakeholders’ disposal to interact with FDA on this issue, including submission of comments" for citizen petition CRN submitted on NAC, Andrew Tantillo, acting associate commissioner for legislative affairs, tells Sen. Mike Lee.
US Meeting Set For CBDs’ Impact On Pregnancies, Gender-Specific Biological, Psychosocial Effects
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.
A Year After US FDA Public Hearing: CBD Demand Soars Along With Need For Safety Data
US cannabis research funding of $189m, growing 65% since 2016, isn’t keeping pace with demand for CBD products with sales projected to surpass $20bn by 2024, says the Collaborative for CBD Science and Safety. It urges industry to accelerate R&D and FDA to move forward with a regulatory framework.